Abstract
Allogeneic stem cell transplant for high-risk aplastic anemia (AA) yields inferior results using conventional cyclophosphamide (CY)-based conditioning. The use of fludarabine (Flu)-based regimens has resulted in improved outcomes in high-risk patients. Limited data are available comparing these two conditioning regimens in such patients. We retrospectively analyzed 192 high-risk patients undergoing matched-related donor transplantation from July 2001 to December 2018. The median age was 19.5 (2–52) years. Patients were divided into 2 groups, Cy200 anti-thymocyte globulin (ATG)20 (Gp1 n = 79) or Flu120–150 Cy120–160 ATG20 (Gp2 n = 113). The risk of graft failure was significantly higher in Gp1, and the majority occurred in patients with >2 risk factors (p = 0.02). The incidence of grade II-IV acute graft versus host disease (GVHD) and chronic GVHD was not significantly different between the two groups. The overall survival (OS) of the study cohort was 81.3 %, disease-free survival (DFS) 76.6 % and GVHD-free relapse-free survival (GRFS) was 64.1%. DFS and GRFS were significantly higher in Gp2 as compared to Gp1: DFS 84.1% versus 68.4 % (p = 0.02), GRFS 77.9% versus 54.4% (p = 0.01), respectively. We conclude that Flu-based conditioning is associated with superior OS, DFS and GRFS as compared to the conventional Cy-based regimen in high-risk AA.
Article PDF
Avoid common mistakes on your manuscript.
References
Sureda, A, Bader, P, Cesaro, S, Dreger, P, Duarte, RF, Dufour, C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours, and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50;1037–56.
Bacigalupo, A, Socié, G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuehrer, M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 2012;97;1142–8.
Lee, S, Yahng, S, Cho, B, Eom, K, Kim, Y, Kim, H, et al. Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia. Bone Marrow Transplant 2016;51;1323.
Locasciulli, A, Oneto, R, Bacigalupo, A, Socié, G, Korthof, E, Bekassy, A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica 2007;92;11–18.
Maury, S, Bacigalupo, A, Anderlini, P, Aljurf, M, Marsh, J, Socié, G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009;94;1312–15.
George, B, Mathews, V, Viswabandya, A, Kavitha, M, Srivastava, A, Chandy, M. Fludarabine and cyclophosphamide based Reduced Intensity Conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant 2007;40;13.
Al-Zahrani, H, Nassar, A, Al-Mohareb, F, Al-Sharif, F, Mohamed, S, Al-Anazi, K, et al. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia. Biol Blood Marrow Transplant 2011;17;717–22.
Iftikhar, R, Satti, TM, Mahmood, SK, Ghafoor, T, Shamshad, GU, Shahbaz, N, et al. Outcome of fludarabine based conditioning in high risk aplastic anemia patients undergoing matched related donor transplantation: a single center study from Pakistan. Biol Blood Marrow Transplant 2019;25;2375–82.
Srinivasan, R, Takahashi, Y, Philip McCoy, J, Espinoza-Delgado, I, Dorrance, C, Igarashi, T, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol 2006;133;305–14.
Resnick, IB, Aker, M, Shapira, MY, Tsirigotis, PD, Bitan, M, Abdul-Hai, A, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol 2006;133;649–54.
Camitta, BM, Rappeport, JM, Parkman, R, Nathan, DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood 1975;45;355–63.
Bacigalupo, A, Hows, J, Gluckman, E, Nissen, C, Marsh, J, Van Lint, MT, et al. Bone Marrow Transplantation (BMT) versus immunosuppression for the treatment of Severe Aplastic Anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol 1988;70;177–82.
Alter, BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Hematol Am Soc Hematol Educ Prog 2017;2017;88–95.
Hicheri, Y, Einsele, H, Martino, R, Cesaro, S, Ljungman, P, Cordonnier, C. Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Transplant Infect Dis 2013;15;251–8.
Shamsi, T, Hashmi, K, Adil, S, Ahmad, P, Irfan, M, Raza, S, et al. The stem cell transplant program in Pakistan–the first decade. Bone Marrow Transplant 2008;42;S114–S7.
Dignan, FL, Clark, A, Amrolia, P, Cornish, J, Jackson, G, Mahendra, P, et al. Diagnosis and management of acute graft‐versus‐host disease. Br J Haematol 2012;158;30–45.
Vigorito, AC, Campregher, PV, Storer, BE, Carpenter, PA, Moravec, CK, Kiem, H-P, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009;114;702–8.
Devillier, R, Labussière-Wallet, H, Clément, L, Yakoubagha, I, Bay, J-O, Gandemer, V, et al. A composite event-free survival end point to evaluate outcome after allogeneic transplantation for severe aplastic anemia: a study on behalf of the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC). Am Soc Hematology 2016;128;2674.
Socié, G. Allogeneic BM transplantation for the treatment of aplastic anemia:current results and expanding donor possibilities. ASH Educ Prog Book 2013;2013;82–6.
Bacigalupo, A, Socié, G, Hamladji, RM, Aljurf, M, Maschan, A, Kyrcz-Krzemien, S, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica 2015;100;696–702.
Scheinberg, P, Young, NS. How I treat acquired aplastic anemia. Blood 2012;120;1185–96.
Kojima, S. Why is the incidence of aplastic anemia higher in Asia? Expert Rev Hematol 2017;10;277–9.
Taj, M, Shah, T, Aslam, SK, Zaheer, S, Nawab, F, Shaheen, S, et al. Environmental determinants of aplastic anemia in Pakistan: a case-control study. J Public Health 2016;24;453–60.
Champlin, RE, Horowitz, MM, van Bekkum, DW, Camitta, BM, Elfenbein, GE, Gale, RP, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73;606–13.
Koh, L, Koh, M, Ng, H, Hwang, W, Goh, Y, Linn, Y, et al. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine. Biol Blood Marrow Transplant 2006;12;887–90.
Schrezenmeier, H, Passweg, JR, Marsh, JC, Bacigalupo, A, Bredeson, CN, Bullorsky, E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110;1397–400.
Sanders, JE, Storb, R, Anasetti, C, Deeg, H, Doney, K, Sullivan, KM, et al. Marrow transplant experience for children with severe aplastic anemia. Am J Pediatr Hematol Oncol 1994; 16;43–9.
Kumar, R, Prem, S, Mahapatra, M, Seth, T, Chowdhary, D, Mishra, P, et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant 2006;37;745.
Kobayashi, R, Yabe, H, Hara, J, Morimoto, A, Tsuchida, M, Mugishima, H, et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006;135;693–6.
Gómez-Almaguer, D, Vela-Ojeda, J, Jaime-Pérez, JC, Gutiérrez-Aguirre, CH, Cantú-Rodríguez, OG, Sobrevilla-Calvo, P, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol 2006;81;157–61.
Storb, R, Thomas, ED, Buckner, CD, Clift, RA, Deeg, HJ, Fefer, A, et al. Marrow transplantation in thirty untransfused patients with severe aplastic anemia. Ann Intern Med 1980;92;30–6.
George, B, Mathews, V, Lakshmi, KM, Melinkeri, S, Sharma, A, Viswabandya, A, et al. The use of a fludarabine-based conditioning regimen in patients with severe aplastic anemia–a retrospective analysis from three I ndian centers. Clin Transplant 2013;27;923–9.
Champlin, RE, Perez, WS, Passweg, JR, Klein, JP, Camitta, BM, Gluckman, E, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007;109;4582–5.
Kim, H, Lee, J-H, Joo, Y-D, Bae, SH, Hyun, MS, Lee, J-H, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol 2012;91;1459–69.
Min, CK, Kim, DW, Lee, JW, Han, CW, Min, WS, Kim, CC. Supplemental peripheral blood stem cells to decrease marrow rejection in adult patients with severe aplastic anemia. Am J Hematol 2002;69;15–22.
Min, C-K, Kim, DW, Lee, JW, Han, CW, Min, WS, Kim, CC. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001;86;303–10.
Markey, KA, MacDonald, KP, Hill, GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014;124;354–62.
Cooke, KR, Luznik, L, Sarantopoulos, S, Hakim, FT, Jagasia, M, Fowler, DH, et al. The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 2017;23;211–34.
George, B, Mathews, V, Viswabandya, A, Srivastava, A, Chandy, M. Fludarabine-based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections. Clin Transplant 2009;23;228–32.
Author information
Authors and Affiliations
Corresponding author
Additional information
Peer review under responsibility of the International Academy for Clinical Hematology Data availability statement:The datasets of current study are available from the corresponding author on email request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Iftikhar, R., Chaudhry, Q.u., Satti, T.M. et al. Comparison of Conventional Cyclophosphamide versus Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched-Related Donor Transplantation. Clin Hematol Int 2, 82–91 (2020). https://doi.org/10.2991/chi.d.200426.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.200426.001